Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies

Total Page:16

File Type:pdf, Size:1020Kb

Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies Robert M. Sharkey, PhD; and David M. Goldenberg, ScD, MD Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey lular biology led the way with the development of mono- With the approval of 2 radiolabeled antibody products for the clonal antibodies and, more recently, with the engineering treatment of non-Hodgkin’s lymphoma (NHL), radioimmuno- of antibodies in various configurations with reduced immu- therapy (RIT) has finally come of age as a new therapeutic nogenicity. It is worth noting that antitumor antibodies modality, exemplifying the collaboration of multiple disciplines, remain one of the best means for selective binding to including immunology, radiochemistry, radiation medicine, suitable targets on cancer cells and have also stimulated the medical oncology, and nuclear medicine. Despite the many challenges that this new therapy discipline has encountered, study of other delivery forms, such as oligonucleotides or there is growing evidence that RIT can have a significant impact aptamers (6,7). However, the use of antibodies in radio- on the treatment of cancer. Although follicular NHL is currently immunotherapy (RIT) is still evolving, with the investiga- the only indication in which RIT has been proven to be effective, tion of new molecular constructs, new radionuclides and clinical trials are showing usefulness in other forms of NHL as radiochemistry, improved dosimetry, prediction of tumor well as in other hematologic neoplasms. However, the treatment response and host toxicities, and better targeting strategies of solid tumors remains a formidable challenge, because the to prevent or overcome host toxicities, particularly myelo- doses shown to be effective in hematologic tumors are insuffi- suppression. The hope is that the advances made for RIT in cient in the more common epithelial cancers. Nevertheless, there has been progress in locoregional applications and in the hematologic malignancies will translate to progress in the treatment of minimal residual disease. There is also optimism therapy of more radioresistant solid tumors. The purpose of that pretargeting procedures, including new molecular con- this article is not to review the many efforts and advances structs and targets, will improve the delivery of radioactivity to made in RIT, but to summarize our views of the current tumors, do so with less hematologic toxicity, and become the status and future prospects. Other reviews may be consulted next generation of RIT. for more comprehensive discussions of this subject (4,5,8–14). Key Words: Antibodies; colorectal cancer; non-Hodgkin’s lym- phoma; pretargeting; radioimmunotherapy HEMATOLOGIC MALIGNANCIES J Nucl Med 2005; 46:115S–127S 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuti- cals Corporation) and 131I-tositumomab (Bexxar; Corixa and GlaxoSmithKline Corporations) are currently the only At the turn of the 19th century, Paul Ehrlich conceived radiolabeled antibodies approved for treatment of cancer. the idea that “magic bullets” could effectively target com- Each is registered for therapy of chemotherapy-refractive, pounds and eradicate sites of disease, but it was not until the follicular (low-grade) NHL, with or without transformation, early 1950s that this idea was first explored with an anti- and uses an antibody that is directed to CD20, an antigen body conjugated to a radionuclide (1). Another quarter of a that is abundantly present on a high percentage of both normal and malignant B-cells. Details of the treatment century would pass before antibody-based tumor localiza- schemes for each of these approved agents are provided in tion was achieved clinically (2). This then led to the first Figure 1. Each is administered at radioactivity dose levels radioimmunodetection products in the mid-1990s (3). In the that result in severe myelosuppression that, for the most first years of the 21st century, the first agent of this type was part, is reversible. A significant portion of patients in the approved for the treatment of non-Hodgkin’s lymphoma registration trials for Zevalin and Bexxar, however, required (NHL) (4,5). The first 30 y of this process were devoted supportive therapy, including platelet transfusions (22% and mostly to the discovery and production of suitable antibod- 15%, respectively), erythropoietin or epoetin alfa (8% and ies, as well as developing radiolabeling technologies. Cel- 7%, respectively), or filgrastim (13% and 12%, respec- tively) (15,16). The overall response rate for 131I-tositu- Received Apr. 12, 2004; revision accepted Aug. 16, 2004. momab in rituximab-refractory patients was similar to that For correspondence or reprints contact: David M. Goldenberg, ScD, MD, reported with 90Y-ibritumomab tiuxetan, suggesting that the Center for Molecular Medicine and Immunology, 520 Belleville Ave., Belleville, NJ 07109. radionuclides are equally effective. However, the selection E-mail: [email protected] of the radionuclide has been shown to be more important for CANCER RADIOIMMUNOTHERAPY • Sharkey and Goldenberg 115S B1 alone has been shown to be active in animal models (37–39). Furthermore, responses were described in patients after they received a pretherapy diagnostic imaging dose (40,41). Anti-CD22 and anti-human leukocyte antigen (anti- HLA) antibodies also have been shown to be active as naked antibodies (42,43). Thus, the antibody itself is likely contributing to the antitumor responses observed with some of the radiolabeled antibodies used in NHL. In contrast, evidence for this has not been documented for the antibod- ies used in RIT of solid tumors. Although the acceptance of these approved treatment modalities appears to be slow, it is important to remember that this technology is still in the early stages of develop- ment. With several opportunities to improve the overall response and survival rates, this treatment modality should FIGURE 1. Comparison of administration conditions for 131I- become more established. For example, RIT is currently tositumomab) and 90Y-ibritumomab tiuxetan. Reprinted with used in patients in whom chemotherapy fails, but clinical permission from Goldenberg, DM. Therapeutic use of radiola- studies using 131I-tositumomab as a frontline treatment for beled antibodies: hematopoietic tumors. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd NHL were highly encouraging, not only because of the ed. London, UK: Churchill Livingstone; 2004:428–434. excellent response rate, but also because the regimen had far fewer side-effects than chemotherapy (44). Press et al. (45) reported encouraging therapeutic results when 131I-tositu- other radiolabeled antibodies being investigated as potential momab was administered as a frontline therapy 4–6 wk therapeutics for NHL, because these antibodies are internal- after standard cyclophosphamide, adriamycin, vincristine, ized and then rapidly catabolized, which favors the use of and prednisone treatment for follicular NHL. It is notable radionuclides that remain inside the cell (17–20). 90Y-ibri- that in this trial hematologic toxicity was more severe with tumomab tiuxetan and 131I-tositumomab each have unique chemotherapy than with RIT. Most of the data for RIT are requirements for use, which have been extensively reviewed based on a single treatment, yet Kaminski et al. (35) re- in several papers (21–26). ported that 9 of 16 patients re-treated with 131I-tositumomab Antitumor responses in NHL occur at very low absorbed after progression responded a second time, with 5 attaining doses (e.g., much less than 1,000 cGy). Koral et al. (27,28) a complete response. Others have reported safety and effi- reported a trend for higher absorbed doses to tumors that cacy of radioantibody treatment in patients who previously ultimately had a complete response, but others have dis- received another radioantibody therapy, and standard che- puted this relationship and even whether the lesions that motherapy can also be given after nonmyeloablative radio- responded were visualized by the radioimmunoconjugate antibody treatment without additional side effects (46–48). (29,30). Although clear evidence for a dose–response rela- Thus, not only can multiple cycles of radioantibody treat- tionship is lacking, it is likely present, but technical limita- ment be given, but RIT can also be integrated safely with tions in the way radiation dose and tumor size are measured various treatment modalities as a means of further improv- create considerable inaccuracies in these estimates. Another ing response. variable is the fact that some antibodies used in these trials Although each radioantibody treatment has established a have therapeutic activity by themselves (31,32). Evidence dosing regimen that ultimately results in a majority of suggests a role for anti-CD20 antibody in enhancing the patients experiencing severe, dose-limiting thrombocytope- therapeutic response from low-dose radiation (33,34). A nia and neutropenia, the tolerance of the therapy is related randomized trial comparing the efficacy of a full course of more to the patient’s treatment history as it affects their rituximab (375 mg/m2/week ϫ 4) with that of 90Y-ibritu- bone marrow status than is the actual radiation dose deliv- momab tiuxetan (250 mg/m2 rituximab/week ϫ 2 with the ered to the red marrow (49). Perhaps further refinement in radiolabeled murine anti-CD20) showed the radiolabeled optimizing the manner in which the radioactivity
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
    CCR FOCUS Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends Martina Steiner and Dario Neri Abstract When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer. Clin Cancer Res; 17(20); 6406–16. Ó2011 AACR. Introduction are immunogenic in humans and thus prevent repeated administration to patients [this limitation was subse- In 1975, the invention of hybridoma technology by quently overcome by the advent of chimeric, humanized, Kohler€ and Milstein (1) enabled for the first time the and fully human antibodies (7)]. Of more importance, production of rodent antibodies of single specificity most radioimmunotherapy approaches for the treatment (monoclonal antibodies). Antibodies recognize the cog- of solid tumors failed because the radiation dose deliv- nate
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Treatment of Cancer.Pptx
    5/3/15 Treatment of Cancer – Chemotherapy, Surgery, Radiation Cancer There is a crabgrass illustration – where you and Immunotherapy… find a batch of crabgrass in a beautiful yard… what do you do? • Cut it – Surgery • Burn it – Radiation • Poison it – Chemotherapy The best approach is to know what caused the crabgrass (it is a kind of grass) and treat it specifically – “Personalized Medicine or Molecular/Targeted Therapy” If we only had enough time Effective Therapies – may Aim of Therapy Cure, Control and/or Relieve the symptoms require better diagnosis • Neoadjuvant chemotherapy: Before • Most diagnosis depends on microscopic/ histopathological analysis (remember the surgery or radiation – to shrink tumor making staging?) it more effectively treated or removed • This method does NOT account for the • Adjuvant chemotherapy: treated after heterologous population of cells nor the surgery or radiation – To deal with undetected various mutations of driver/passenger genes, cells, microtumors… specific oncogenes or tumor suppressors. • Some markers are being used but not widely • Palliative chemotherapy: To treat patient and the number of oncologists that and reduce symptoms – improve quality of understand these markers and use them is life, not treat underlying cause or curative questionable except in most advanced cases “Targeted” Cancer Treatment Cancer Targets How does it work? Attack targets which are specific for the cancer cell and are critical for its survival or for its malignant behavior Why is it better than chemotherapy? More specific for cancer cells – chemotherapy hits rapidly growing cells not all cancer cells grow that rapidly some normal cells grow rapidly Possibly more effective From National Cancer Institute, US National Institutes of Health.
    [Show full text]
  • Translational Research in Surgical Disease
    REVIEW ARTICLE Translational Research in Surgical Disease Alexander Stojadinovic, MD; Nita Ahuja, MD; Susanna M. Nazarian, MD, PhD; Dorry L. Segev, MD; Lisa Jacobs, MD; Yongchun Wang, MD; John Eberhardt, MD; Martha A. Zeiger, MD Objective: To review cutting-edge, novel, imple- geon familiar with cutting-edge and novel research in their mented and potential translational research and to pro- field of expertise and interest. vide a glimpse into rich, innovative, and brilliant ap- proaches to everyday surgical problems. Data Synthesis: Articles that met criteria were sum- marized in the manuscript. Data Sources: Scientific literature and unpublished re- sults. Conclusions: Multiple avenues have been used for the dis- coveryofimprovedmeansofdiagnosis,treatment,andoverall Study Selection: Articles reviewed were chosen managementofpatientswithsurgicaldiseases.Theseavenues based on innovation and application to surgical dis- have incorporated the use of genomics, electrical impedence, eases. statistical and mathematical modeling, and immunology. Data Extraction: Each section was written by a sur- Arch Surg. 2010;145(2):187-196 HE FOLLOWING REVIEW OF risk of malignancy ranges from 5% to 10% cutting-edge, novel, imple- for follicular lesions (atypia) of undeter- mented and potential trans- mined significance, 20% to 30% for fol- lational research is meant to licular neoplasms, and 50% to 75% for provide a glimpse into rich, nodules with cytological features suspi- Tinnovative, and brilliant approaches to ev- cious of malignancy.1 Because cytology re- eryday surgical problems. It is written pri- sults are indeterminate in up to one- marily by young, innovative surgical sci- third of FNABs, the frequency of diagnostic entists in their field of interest and often or nontherapeutic thyroid resection is sig- in their field of research.
    [Show full text]
  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
    Pure Appl. Chem., Vol. 84, No. 5, pp. 1113–1295, 2012. http://dx.doi.org/10.1351/PAC-REC-11-06-03 © 2012 IUPAC, Publication date (Web): 16 February 2012 IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)* Douglas M. Templeton1,‡, Michael Schwenk2, Reinhild Klein3, and John H. Duffus4 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; 2In den Kreuzäckern 16, Tübingen, Germany; 3Immunopathological Laboratory, Department of Internal Medicine II, Otfried-Müller-Strasse, Tübingen, Germany; 4The Edinburgh Centre for Toxicology, Edinburgh, Scotland, UK Abstract: The primary objective of this “Glossary of Terms Used in Immunotoxicology” is to give clear definitions for those who contribute to studies relevant to immunotoxicology but are not themselves immunologists. This applies especially to chemists who need to under- stand the literature of immunology without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical immunology insofar as they are necessary for a self-contained document, and particularly terms related to diagnos- ing, measuring, and understanding effects of substances on the immune system. The glossary consists of about 1200 terms as primary alphabetical entries, and Annexes of common abbre- viations, examples of chemicals with known effects on the immune system, autoantibodies in autoimmune disease, and therapeutic agents used in autoimmune disease and cancer. The authors hope that among the groups who will find this glossary helpful, in addition to chemists, are toxicologists, pharmacologists, medical practitioners, risk assessors, and regu- latory authorities. In particular, it should facilitate the worldwide use of chemistry in relation to occupational and environmental risk assessment.
    [Show full text]
  • Targeted Radionuclide Therapy of Human Tumors
    Review Targeted Radionuclide Therapy of Human Tumors Sergey V. Gudkov 1,2,3,*, Natalya Yu. Shilyagina 1, Vladimir A. Vodeneev 1 and Andrei V. Zvyagin 1,4 Received: 26 September 2015; Accepted: 22 December 2015; Published: 28 December 2015 Academic Editors: William Chi-shing Cho and Anthony Lemarié 1 Laboratory of Optical Theranostics, Lobachevsky Nizhny Novgorod State University, Gagarin Ave. 23, Nizhny Novgorod 603950, Russia; [email protected] (N.Y.S.); [email protected] (V.A.V.); [email protected] (A.V.Z.) 2 Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Institutskaya St, 3, Pushchino, Moscow 142290, Russia 3 Prokhorov Institute of General Physics, Russian Academy of Sciences, Vavilova St, 38, Moscow 119991, Russia 4 ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, Sydney 2109, Australia * Correspondance: [email protected]; Tel.: +7-4967-739-497 Abstract: Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.
    [Show full text]
  • Improving the Efficacy of Antibody-Based Cancer Therapies
    REVIEWS IMPROVING THE EFFICACY OF ANTIBODY-BASED CANCER THERAPIES Paul Carter A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies. PHAGE DISPLAY Antibodies are finally realizing their potential as anti- relapsed low-grade non-Hodgkin’s lymphoma,only Technology for displaying a cancer therapeutics: since 1995, five antibodies have about half of the patients responded7. This included protein (or peptide) on the been approved for the treatment of cancer (TABLE 1). 6% COMPLETE and 42% PARTIAL RESPONSES from 166 surface of a bacteriophage, Additional approvals will surely follow from among patients, similar results to those obtained with a single- which contains the gene(s) 1,2 that encodes the displayed the 20 or so antibodies now in oncology trials , agent cytotoxic chemotherapeutic in this group of protein(s), thereby physically including 10 that have advanced to Phase III trials or patients. These data, combined with the mild toxicity linking the genotype and further (TABLE 1). profile of Rituxan, led the United States Food and Drug phenotype. The emergence of antibodies as therapeutics was Administration (FDA) to approve Rituxan for relapsed VALENCY made possible by the advent of technologies designed to indolent lymphoma. Unfortunately, the median 7 For antibody-derived overcome the main limitations of mouse monoclonal RESPONSE DURATION was only about 12 months . In a Phase molecules, this refers to the antibodies (mAb) — immunogenicity of these foreign III study of trastuzumab (Herceptin) — a humanized number of binding sites for the proteins in patients, inefficient effector functions (see mAb against the receptor tyrosine kinase ERBB2 (also cognate antigen(s).
    [Show full text]
  • Ovarian Cancer
    Systemic Therapy of Epithelial Ovarian Cancer Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 5th ESO-ESMO Eastern European and Balkan Region Masterclass in Medical Oncology, Belgrade, June 15-20, 2018 Conflict of Interest Disclosure • Participates in Advisory Boards of: AstraZeneca, Incyte, Innate Pharma, Merck KGaA, Merck Sharp & Dome Corp, PCI Biotech, Synthon Biopharmaceuticals, • Lecturer fee from: Merck-Serono, Sanofi, Bristol Myers Squibb Epithelial Ovarian Cancer Milestones • Surgery according to FIGO guidelines – At least LND and peritoneal staging in early ovarian cancer – Upfront maximal surgical debulking in advanced ovarian cancer • Chemotherapy evolution – Introduction of platinum compounds – Introduction of taxanes • The set-up of international collaboration (1997) Ovarian Cancer: FIGO Staging Surgical exploration Diagnostic • Vertical incision • Peritoneal fluid → cytology (or saline irrigation) • Scrupulous inspection - right diaphragm - liver, serosa, parenchyma • Biopsies of contralateral ovary, retroperitoneal LN and suspicious changes on the peritoneum, omentum Therapeutic • Early disease – TAH + BSO, omentectomy, LND • Advanced disease – debulking surgery FIGO Staging (2017) of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma IA Confined to one ovary, intact capsule, no tumor on surface (Ov;FT), no malignant cells in ascites or peritoneal washings IB Confirmed to both ovaries (same criteria as IA) IC IA or IB + surgical spill/capsule rupture/tumor on surface/pos.
    [Show full text]
  • A61K9/51 (2006.01) — with International Search Report (Art
    ) ( 2 (51) International Patent Classification: Published: A61K9/51 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 19/033 875 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: 24 May 2019 (24.05.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/676,169 24 May 2018 (24.05.2018) US (71) Applicant: ELEKTROFI, INC. [US/US]; 75 Kneeland Street, 14th Floor, Boston, MA 021 11 (US). (72) Inventors: COFFMAN, Chase; 86 Worcester Street, Unit 3, Boston, MA 021 18 (US). CHARLES, Lyndon; 600 Main St Apt 3, Medford, MA 02155 (US). BROWN, Paul; 156 W 6th St, Unit 2, Boston, MA 02127 (US). DADON, Daniel, Benjamin; 2 Garden Court, Apt. 1, Cambridge, MA 02138 (US). LIU, Lisa; 111 Bartlett Street, Apt 2, Somerville, MA 02145 (US). SHADBAR, Sadiqua; 1307 Commonwealth Avenue, Apt 9, Allston, MA 02135 (US). SUDRIK, Chaitanya; 7 1 Elm Street, Apartment #2, Cam¬ bridge, MA 02139 (US). (74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. A61K 31/437 (2018.01) 11 A61K 31/496 (2018.01) N° 18380 A61K 31/5377 (2018.01) A61P 35/02 (2018.01) FASCICULE DE BREVET D'INVENTION 21 Numéro de dépôt : 1201700302 73 Titulaire(s): PCT/US2016/015727 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 29/01/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): US n° 62/111,604 du 03/02/2015 72 DI PAOLO Julie A. (US) TUMAS Daniel B. (US) JONES Randall Mark (US) 24 Délivré le : 31/08/2018 74 Mandataire: GAD CONSULTANTS SCP, P.O. Box 13448, YAOUNDE (CM). 45 Publié le : 02.11.2018 54 Titre: Combination therapies for treating cancers. 57 Abrég é : Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration entospletinib and a Bcl-2 inhibitor, such as venetoclax, navitoclax, and ABT-737. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18380 COMBINATION THERAPIES FOR TREATING CANCERS FIELD The present disclosure relates generally to therapeutics and compositions for treating cancers, and more specifically to the use of Spleen Tyrosine Kinase (Syk) inhibitors 5 in combination with B-cell CLL/lymphoma 2 (Bc1-2) inhibitors for treating cancers. BACKGROUND Syk inhibitors useful as anticancer agents include entospletinib, discussed in Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL), Sharman et al., Blood, 124(21), Dec.
    [Show full text]
  • Wo 2010/095940 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 26 August 2010 (26.08.2010) WO 2010/095940 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 49/00 (2006.01) A61P 25/28 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 31/12 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/NL20 10/050082 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 19 February 2010 (19.02.2010) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/154,083 20 February 2009 (20.02.2009) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): TO- TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, BBB HOLDING B.V.
    [Show full text]